A Registry for Patients Treated on the Clinical Trial TAX 3503
NCT ID: NCT01813370
Last Updated: 2022-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
52 participants
OBSERVATIONAL
2013-03-31
2022-03-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)
NCT00514917
Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer
NCT00456989
Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly
NCT00161252
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
NCT00776594
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pts with prostate cancer
Patients who have progressed or hit their 36 month post treatment date between the closure of TAX3503 and the activation of this TAX3503 Registry protocol will be permitted on the study to capture their date of progression or their 36 month post treatment progression free date.
No intervention
No intervention is planned as part of this protocol. Historical data will be transferred to MSK via electronic data transfer. Patient's PSA, testosterone, and vital status data will be transferred to MSK via electronic data transfer.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No intervention is planned as part of this protocol. Historical data will be transferred to MSK via electronic data transfer. Patient's PSA, testosterone, and vital status data will be transferred to MSK via electronic data transfer.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. The patient must have been registered to TAX3503
2. The patient must not have met the definition of progression as defined in TAX3503 while on TAX3503 Patients who have progressed or hit their 36 month post treatment date between the closure of TAX3503 and the activation of this TAX3503 Registry protocol will be permitted on the study to capture their date of progression or their 36 month post treatment progression free date.
Exclusion Criteria
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laval University
OTHER
Vancouver General Hospital
OTHER
London Health Sciences Centre
OTHER
Centre Hospitalier Universitaire de Montreal - Hospital Notre-Dame
UNKNOWN
Princess Margaret Hospital, Canada
OTHER
CancerCare Manitoba
OTHER
Tom Baker Cancer Centre
OTHER
Urocentrum Praha s.r.o.
UNKNOWN
Fakultní nemocnice Na Bulovce
UNKNOWN
Hospital Jablonec nad Nisou, p.o
UNKNOWN
Klaipėda University
OTHER
Lithuanian University of Health Sciences
OTHER
Oncology Institute of Vilnius University
UNKNOWN
Fakultna Nemocnica s poliklinikou J.A. Reimana Presov, Klinika urologie
UNKNOWN
Martinska Fakultna Nemocnica, Urologicke klinika
UNKNOWN
Fakultna nemocnica s poliklinikou
UNKNOWN
BratislavaNemocnica ak. L Derera, Urologicka klinika
UNKNOWN
Urologic Consultants of Southeastern PA
OTHER
Columbia University
OTHER
GU Research Network, LLC
OTHER
Carolina Urologic Research Center
OTHER
Lancaster Urology
UNKNOWN
Kansas City Veteran Affairs Medical Center
FED
Urology San Antonio Research PA
UNKNOWN
University of Texas Southwestern Medical Center
OTHER
University of Cincinnati
OTHER
St. Alexius Medical Center Clinical Research Services
UNKNOWN
Barbara Ann Karmanos Cancer Institute
OTHER
Johns Hopkins University
OTHER
Duke University
OTHER
Vanguard Urologic Research Foundation
OTHER
The Urological Institute of Northeastern NY
UNKNOWN
Urology Associates Medical Group
UNKNOWN
Hospital de Sabadell
OTHER
Lahey Clinic
OTHER
San Bernardino Urological Associates
UNKNOWN
Columbus Urology
UNKNOWN
Niepubliczny Specjalistyczny Onkologiczny Zaklad Opienki Zdrowotnej
UNKNOWN
Vinzenzkrankenhaus Hannover, Urologische Abteilung (Uro-Onkologie)
UNKNOWN
Memorial Sloan Kettering Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Morris, MD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
John Hopkins Medical Center
Baltimore, Maryland, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Urological Associates of Lancaster
Lancaster, Pennsylvania, United States
Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States
Cancer Care Manitoba
Winnipeg, Manitoba, Canada
Hospital of Lithuanian University Health Sciences Kauno Klinikos
Kaunas, Klinikos, Lithuania
Klaipeda University Hospital
Klaipėda, , Lithuania
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Memorial Sloan Kettering Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12-225
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.